ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation
Authors:
- Karin Lövgren BengtssonKBKarin Lövgren Bengtsson
- Bror MoreinBMBror Morein
- Albert Dme OsterhausAOAlbert Dme Osterhaus
- 1 April 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 10 (4) , 401-403
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-MatrixVaccine, 2010
- ISCOMATRIX™ vaccines: Safety in human clinical studiesHuman Vaccines, 2010
- Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in miceVaccine, 2009
- Adjuvant effects of saponins on animal immune responsesJournal of Zhejiang University-SCIENCE B, 2007
- Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21Vaccine, 2001
- Functional aspects of iscomsImmunology & Cell Biology, 1998
- Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition.Journal of Experimental Medicine, 1992
- Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMsNature, 1990
- The requirement of lipids for the formation of immunostimulating complexes (iscoms)Biotechnology and Applied Biochemistry, 1988
- Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped virusesNature, 1984